CXCL12 and colorectal carcinoma: The inhibition of CXCL12 partially counteracted the enhancing effect of α-HSCs, which were activated by MIR181A1HG-overexpressing CRC cell-derived EVs, on CRLM (Fig. 6d-f, Supplementary Fig. S8c).